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Simplified Novel Muraymycin Analogues; using a Serine Template 
Strategy for Linking Key Pharmacophores 
Bhautikkumar Patel,[a,b,c] Rachel V Kerr,[d] Dr Alpeshkumar K Malde,[e,f] Dr Matthew Zunk,[a,b,c] Prof 
Timothy DH Bugg,[d] A/Prof Gary Grant,[a,b,c] and Dr Santosh Rudrawar*[a,b,c] 
Abstract: The present status of antibiotic research requires an urgent 
invention of novel agents that act on multidrug resistant bacteria. The 
World Health Organization (WHO) has classified antibiotic-resistant 
priority bacterium into critical, high and medium priority according to 
the urgency of need for new antibiotics. Naturally occurring uridine-
derived ‘nucleoside antibiotics’ have shown promising activity against 
numerous priority resistant organisms via inhibition of the 
transmembrane protein MraY (translocase I), which is yet to be 
explored in a clinical context. The catalytic activity of MraY is an 
essential process for bacterial cell viability and growth including that 
of priority organisms. Muraymycins are one subclass of naturally 
occurring MraY inhibitors. Despite having potent antibiotic properties, 
the structural complexity of muraymycins advocates for simplified 
analogues as potential lead structures. Herein we report the 
systematic structure-activity relationship (SAR) study of serine 
template linked simplified muraymycin-type analogues. This 
preliminary SAR lead study of serine template analogues has 
successfully revealed that the complex structure of naturally occurring 
muraymycins could be easily simplified to afford bioactive scaffolds 
against resistant priority organisms. This study will pave the way for 
the development of novel antibacterial lead compounds based on a 
simplified serine template.     
Introduction 
Bacterial resistance against clinically used antibiotics is an 
emerging health concern in contemporary healthcare.1,2 To 
address growing global resistance, the World Health Organization 
(WHO) has published a list of antibiotic-resistant priority 
pathogens.3 The major objective of publishing this list was to 
guide and promote research and development (R&D) of new 
unexplored classes of antibiotics aimed at treating multidrug 
resistant pathogens.4 Ideally, these novel antibiotics should target 
clinically unexploited modes of action to avoid cross resistance 
with existing drugs. Bacterial cell-wall peptidoglycan layer 
biosynthesis has been a promising antibacterial target for 
decades led by the discovery of β-lactam (penicillin) and 
glycopeptide (vancomycin) classes of antibiotics.5 However, 
these cell wall inhibitors target the late extracellular steps of 
peptidoglycan synthesis. The early intracellular steps of 
peptidoglycan synthesis are not well explored in clinical context. 
Therefore development of antibacterial agents targeting enzymes 
involved in these initial stages could provide an exciting 
opportunity to meet the current need for novel targets.6 The 
transmembrane enzyme MraY (phospho-N-acetylmuramoyl-
pentapeptide-transferase; translocase I) is one such enzyme with 
its active site located on the cytosolic side of the membrane, 
which fulfils the requirement of a novel target.7 MraY catalyses the 
first membrane-associated step of peptidoglycan formation which 
involves transfer of an UDP-N-acetylmuramoyl (UDP-MurNAc)-
pentapeptide (-L-Ala--D-Glu-diaminopimelic acid/L-Lys-D-Ala-D-
Ala) (Park’s nucleotide) to the lipid carrier [C55 isoprenoid 
phosphate (C55-P)/C50 decaprenyl phosphate (C50-P)], resulting in 
the formation of lipid I (undecaprenyl-pyrophosphoryl-MurNAc-
pentapeptide) (Figure 1).8 
 
Figure 1. Reaction catalysed by the bacterial transmembrane enzyme MraY.8 
The MraY enzyme (translocase I) has been identified as the 
target of bacterial nucleoside antibiotics, a class of bacterial 
derived natural products containing a nucleoside core 
structure.9,10 Due to their promising antibacterial activity against a 
broad spectrum of Gram-positive bacteria, nucleoside antibiotics 
have been considered as promising lead structures for the 
development of novel antibacterial agents. Based on their 
structural characteristics, nucleoside antibiotics have been 
classified into four classes: i) ribosamino-uridines, ii) 
uridylpeptides, iii) tunicamycins, and iv) capuramycin.11,12 
Muraymycins belong to the family of ribosamino-uridine type 
nucleoside antibiotics, which were first discovered as a collection 
of 19 structurally related secondary metabolites from a broth of a 
Streptomyces sp. in 2002.13 More recently novel members of the 
muraymycins class of natural products have been isolated from 
the same bacterial strains.14 Muraymycin A1 has been reported 
active against Gram-positive Staphylococcus (MIC: 2-16 g/mL), 
Enterococcus (MIC: 16-64 g/mL), as well as Gram-negative E. 
coli (MIC: <0.03 g/mL).15  
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In general, the muraymycin scaffold contains a (5S, 6S)-
glycyluridine (GlyU) core structure linked to a urea peptide moiety 
by an alkyl linker.16 The urea peptide contains the non-
proteinogenic amino acid epicapreomycidine derived from a cyclic 
arginine derivative. Based on the structural diversity of the central 
L-leucine (Leu) unit of the peptide moiety, muraymycins have 
been classified into four sub-classes, being series A to D (Figure 
2).17 Subclasses A, B and C contain a (3S)-3-hydroxyl-L-leucine, 
which are further distinguished between each other by varying 
substitutions at the 3-hydroxyl position. Series A muraymycins 
(e.g., A4 1) are 3-O-acylated with -functionalised fatty acids 
terminating with a guanidinium moiety. While series B 
muraymycins (e.g. B5 2) are 3-O-acylated with unfunctionalised 
terminally branched fatty acids. The C-type muraymycins (e.g. C2 
3) are not O-acylated at the 3-hydroxy-L-leucine, and the D-series 
of muraymycin D2 4) contain proteinogenic non-hydroxylated L-
leucine at this position (Figure 2).    
 
Figure 2. Chemical diversity of naturally occurring muraymycin sub-classes A-
D 
A significant challenge in order to create drug-like 
compounds is muracycin’s complex and synthetically challenging 
structure.18a-f,19,20a-b To date, two approaches are reported in the 
literature towards the total synthesis of naturally occurring 
muraymycins.18a,b Tanino et al. reported the first total synthesis of 
muraymycin D2 in total 18 steps with a 4.3% overall yield.18b While 
the second report for stereo-controlled total synthesis of 
muraymycin D1 was published by Kurosu et al. in 19 steps with 
overall yield of only 15.9%.18a Moreover, Kurosu et al. evaluated 
muraymycin D1 and its amide derivatives for antibacterial 
activity.18a These muraymycin analogues exhibited growth 
inhibitory activity against Mycobacterium tuberculosis (MIC50 
1.56-6.25 g/mL) and strong enzyme inhibitory activities against 
the bacterial phosphotransferases (MurX and WecA) (IC50 = 
0.096-0.69 M).18a Furthermore, Kurosu et al. created an 
anticancer DPAGT1 inhibitor from a muraymycin biosynthetic 
intermediate.18c Another group of scientists from Wyeth also 
worked on the semisynthetic access and have synthesised a total 
of 16 derivatives of muraymycin C1.18d Structure-activity 
relationship (SAR) studies of these synthesised analogues 
suggested that the mono-substituted derivatives demonstrated 
good inhibitory activity against MraY or MurG (6.25 g/mL), which 
importantly, correlated with the lipophilicity of the substituents 
introduced.18d Kristin et al. reported solid phase-based synthetic 
strategy for accessing muraymycin analogues.18e Recently, Anna 
et al. explored variations in the nucleoside unit of muraymycin 
antibiotics.18f       
To address this synthetic complexity of muraymycin-based 
natural products, the prime goal of our research is to investigate 
bioactive, structurally simplified muraymycin analogues, which 
are active against a range of bacterial strains. Herein, we describe 
the full details of our efforts to simplify the complex structure of 
muraymycins based on a serine template strategy for linking key 
pharmacophores. This study includes a preliminary SAR for our 
serine template linked simplified muraymycin analogues toward 
discovery of novel structures effective against a range of drug-
resistant bacterial strains.  
Results and Discussion 
Design 
To achieve the primary aim of synthesising simplified 
analogues of muraymycins, it was essential to understand the 
structural orientation of the key pharmacophores present in the 
muraymycins. To start,  key interactions reported for the co-crystal 
structure of MraY (Aquifex aeolicus) in complex with the 
muraymycin D2 4 (Figure 3), were investigated.21 This 
crystallographic study revealed that the 5-aminoribosyl and uracil 
moieties of muraymycin D2 (MD2) bind to the nucleoside-binding 
pocket of MraY like a two-pronged electrical plug inserted into a 
socket.21 Moreover, these interactions were found to be the most 
critical for binding of muraymycin D2 with the MraY enzyme.21 
Specifically, the 5-amino group of the aminoribose moiety 
interacts with Asp-193 through a hydrogen bond and an 
electrostatic interaction.21 The importance of the aminoribose 
moiety has been substantiated.  A 5’-defunctionalised (5’-deoxy) 
muraymycin analogue was essentially inactive.22 Another very 
specific key interaction found was for the uracil nucleobase, which 
binds in a neighboring pocket interacting with Asn-255, Asp-196, 
Lys-70 through hydrogen bonding as well as with Phe-262 via -
stacking.21 These crystallographic findings were found to be in line 
with reported literature while evaluating the core aminoribosylated 
glycyluridine (GlyU) against MraY (from Escherichia coli).23 It was 
found that the core aminoribosylated glycyluridine unit exhibit 
significant anti-MraY activity (IC50 = 50 M), reflecting the minimal 
structural requirement responsible for antibacterial activity against 
MraY (from Escherichia coli).23 After having sufficient literature 
reports supporting the aminoribose and uridine moieties as an 
essential structural requirement for interaction in the active site of 
MraY,21-23 it was decided to retain both the pharmacophores 
within our intended simplified muraymycin scaffold. 




Figure 3. Key interactions of muraymycin D2 with the MraY enzyme (PDB: 
5CKR).21 
  Next, regarding substitutions on the core pharmacophore, 
the literature reports that there is strong hydrophobic interaction 
between muraymycin D1 and the MraY hydrophobic tunnel.24 The 
significant antibacterial activity of lipophilic side chain containing 
molecules suggests that the side chain itself might be contributing 
to the membrane permeability of the molecules as MraY is an 
integral membrane protein and its active site exists on the 
cytoplasmic side of the membrane.24 As the peptidoglycan lipid 
bilayer is a common barrier for bacteria, incorporating a lipophilic 
group appears necessary in simplified analogues to afford any 
antibacterial activity.24 Following the trend reported for inclusion 
of a lipophilic side chain,24 it was decided to retain this 
characteristic while designing our simplified muraymycin scaffold. 
In this work, the principle objective was to link key 
pharmacophores with a simplified linker to afford rapid access to 
biologically active muraymycins analogues. Having encountered 
the significant contribution of the 5-aminoribose,21-23 uridine21,23 
and lipophilic side chain,24 we turned our attention to link these 
pharmacophores together to achieve bioactive muraymycins. 
Naturally occurring muraymycins contain a 5-glycyluridine core 
unit with specific stereochemistry to hold key pharmacophores in 
a specific orientation. Synthetic access to this 5-glycyluridine 
(GlyU) core unit is not trivial and involves multi-step challenging 
synthetic routes.25 Henceforth, to achieve the prime objective of 
chemically simplified muraymycins analogues, we have selected 
a serine template as a linker to which the desired key 
pharmacophores can be linked via conventional amide-coupling 
methodologies (5, Figure 4). Additionally, we also aimed to vary 
the lipophilic side chain by investigating the linear carbon chain 
length to achieve optimised antibacterial activity. Moreover, as 
revealed in the X-ray co-crystal structure,21 orientation of both 5-
aminoribosyl and uracil moieties of muraymycin is crucial for 
binding with the MraY enzyme. So, in this proof-of-principle study, 
we aimed to investigate the stereochemical outcome of the 
proposed serine template by using both enantiomers L and D-
serine amino acids as starting points, while performing total 
synthesis of serine template analogues. 
 
Figure 4. The proposed design of our simplified serine template-based 
muraymycin analogous. 
Chemistry 
Investigation of the serine template basic scaffold  
The SAR study of the serine template linked truncated 
muraymycins analogues was initiated by synthesis and biological 
evaluation of the core serine template (L-serine) linked structure 
6, comprising uridine, 5-aminoribose and octanoic acid as key 
pharmacophores. This core serine template linked molecule 6 
could be synthesised from their synthetic equivalents, including 
the isopropylidene protected 5-amino uridine 7, the ribose 
building block 8 (glycosyl donor) and the serine template (glycosyl 
acceptor) 13 as described in retrosynthetic analysis (Figure 5).  
 
 
Figure 5. The retrosynthetic analysis of core serine template (L-serine) linked 
structure 6. 
Synthesis of the serine template based muraymycin 
analogue 6 was started by independently synthesising each of 
building blocks via modified literature reported methods. The 
isopropylidene protected 5-amino uridine 7 was synthesised from 
commercially available uridine in four synthetic steps in 
quantitative yields (58%).26 After protection of the secondary 
hydroxyl groups (2,3-diol) of uridine with isopropylidene unit, the 
primary hydroxyl group (5-hydroxyl) was activated through 
addition of a p-toluenesulfonyl ester to produce a tosylate product. 
Subsequent nucleophilic substitution of the tosyl group with NaN3 
gave the azido derivative in high yield (95%). The building block 
7 was prepared by reduction of the corresponding isopropylidene 
protected 5'-azido uridine readily obtained from commercially 
available uridine in four steps, according to known routes.26 To 
avoid the undesired Michael addition already described in 
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was preferred and its duration was optimised to limit the formation 
of over reduced side product. In these optimised conditions (Pd/C, 
MeOH, 1 hour) the expected amine 7 was obtained in 90% yield, 
it was used without further purification in the next reaction due to 
its inherent instability 
 Synthesis of the ribose building block 8 as a glycosyl donor 
was carried out concurrently. Prior to synthesis, a thorough 
literature search related to key structural features that 
aminoribose linkage should contain to have antibacterial active 
was undertaken.28 Importantly, ribosyl building blocks must be β-
glycosides to retain antibacterial activity, in naturally occurring 
muraymycins.28a The introduction of a 5-aminoribose moiety in a 
β-selective manner was a major challenge towards the total 
synthesis of our simplified serine template analogues.28a Hirano 
et al. have reported an optimised protocol towards this desired 
outcome.28a They established that to achieve β-selectivity for the 
glycosylated product, the ribofuranoside must have a 3-
pentylidene protecting group across the 2,3-diol, a fluoride leaving 
group at C-1 and an azide group at the C-5 position.28a Therefore, 
based on this report we decided to use the optimised ribose 
building block 8 as our glycosyl donor,28a starting the synthesis 
from commercially available D-ribose. 
 In order to assemble the various synthetic fragments 
together, we also required synthesis of the serine template 
(glycosyl acceptor) (Scheme 1). For the preparation of this 
compound, commercially available Fmoc-Ser(tBu)-OH 9 (L-
isomer) or 10 (D-isomer) was first converted into the allyl ester L-
11 or D-12. The tert-butyl ether was then deprotected with TFA to 
afford the desired serine intermediate (glycosyl acceptor) L-13 or 
D-14 ready for the glycosylation reaction with 8. Having all the 
building blocks in hand, we first planned to couple the uridine 7 
and ribose 8 together with the serine template L-13 or D-14 
followed by linking of the lipophilic side chain. The Hirano et al.28 
had evaluated different reaction conditions for this transformation 
such as using various activators like BF3·OEt2, AgOTf/Cp2HfCl2, 
AgOTf/SnCl2 (or) AgClO4/SnCl2 under varying temperature 
conditions. They observed the use of BF3·OEt2 as an activating 
agent at 0°C was the best outcome in comparison with other 
conditions.28 The ribosylation reaction was followed as reported 
by the Hirano et al.28 and reproduced successfully yielding the 
glycosylated product with only β-anomer L-15 or D-16. After 
purification, the glycosylated product L-15 or D-16 were reacted 
for deallylation to afford the corresponding acid compounds. 
However, initial deallylation attempts by using Pd(PPh3)2Cl2 and 
phenylsilane resulted in undesired side product with reduction of 
the azide functionality. This was assumed due to the inherent 
reduction properties of organosilane (phenylsilane) to act as a 
hydride donor. The issue was resolved by replacing phenylsilane 
with N-methylaniline for deallylation of the glycosylated products 
L-15 or D-16, which afforded the desired corresponding acid 
intermediates L-17 or D-18 efficiently (Scheme 1).     
 
Scheme 1. Reagents and conditions: a) allyl bromide, DIPEA, acetonitrile, 40°C, 
4 h, 90% (for comd. 11), 87% (for comd. 12) b) TFA:DCM (1:1), rt, 1 h, 85% (for 
comd. 13), 84% (for comd. 14), c) BF3·OEt2, CH2Cl2, MS 4Å, 0°C, 1 h, 62% (for 
comd. 15), 61% (for comd. 16), d) Pd(PPh3)4, CH2Cl2, N-methylaniline, rt, 1 h, 
84% (for comd. L-17), 82% (for comd. D-18). 
After the successful linking of the ribose intermediate 8 with 
the serine template (either in 15 or 16), we planned to introduce 
the uridine pharmacophore 7 on to the serine template. The plan 
was executed by reacting either acid intermediates L-17 or D-18 
with the previously synthesised 5-amino uridine 7 via a 
conventional amide coupling reaction (Scheme 2). The resulting 
amide product L-19 or D-20 was further reacted for Fmoc 
deprotection to yield the corresponding amino compound L-21 or 
D-22 (Scheme 2). This amine product (21 or 22 Scheme 2) is an 
advanced precursor for the synthesis of our target serine template 
analogues.       
 
Scheme 2. Reagents and conditions: a) EDC·HCl, HOBt, DMF, rt, overnight, 
84% (for comd. 19), 82% (for comd. 20), b) piperidine (20%), DMF, rt, 1 h. 
After optimisation of the conditions toward the advanced 
stage amine intermediate 21 and 22, we focused on preparing our 
target structures. This work began by optimisation towards the 
western zone of muraymycins, preparing the synthetically 
accessible core structure 6, having three building blocks including 
the uridine, the aminoribose and lipophilic side chain (octanoic 
functional group) linked together onto the serine template. The 
designed target molecule 6 was synthesised starting from 21 in 
three reaction steps (Scheme 3). Firstly, the free amino group of 
the amine product 21 was reacted for amide coupling with 
octanoic acid. Next the azide group of ribose was subsequently 
reduced to the amine under Staudinger reaction conditions. 
Finally, the target compound 6 was produced by a global acidic 
deprotection of the amino intermediate with 80% TFA in water 




















































































Scheme 3. Reagents and conditions: a) EDC·HCl, HOBt, DMF, rt, overnight, b) 
PPh3, H2O, THF/toluene (1:1), 50°C, 18 h, c) aqueous TFA (80%), rt, 6 h, 26% 
in 4 steps.   
Investigation of the lipophilic side chain 
Owing to the lipophilic side chain contribution toward the 
membrane permeability of muraymycins, further work was carried 
out to investigate the importance of this moiety. We wanted to 
evaluate the effect of increasing lipophilicity of the synthetically 
accessible core structure 6, and how that impacted on 
antibacterial properties. Therefore, different target molecules 
were designed with varied lipophilicity in the side chain (23, Figure 
6).  
 
Figure 6. The proposed serine template (L-serine) linked scaffold with varied 
lipophilic side chains 23 
 
 Previous SAR studies have reported that addition of a 
lipophilic side chain beyond octanoic acid to nonanoic 24, 
undecanoic 26 and tridecanoic 28 functional groups helped 
increase antimicrobial activity. Therefore, we began work on 
inducing increased chain length intermediates to mimic the most 
active natural product muraymycin A1 (C13 carbon length). 
Furthermore, introduction of unsaturation increases 
hydrophobicity of the molecule, which should enhance membrane 
permeability. With this idea in mind, we also synthesised 
extended target molecules having linear lipophilic side chain with 
unsaturation, such as 8-nonenoic 25 and undecylenic 27 
functional groups (Scheme 4). At this stage, all of the synthesised 
target molecules (24-28) were evaluated for antibacterial activity 
(see biological evaluation section). 
 
Scheme 4. Reagents and conditions: a) EDC·HCl, HOBt, DMF, rt, overnight, b) 
PPh3, H2O, THF/toluene (1:1), 50°C, 18 h, c) aqueous TFA (80%), rt, 5-6 h, 37% 
(for comd. 24), 31% (for comd. 25), 36% (for comd. 26), 27% (for comd. 27), 
29% (for comd. 28).   
Investigation of the amino acid spacer 
After the successful creation of the lipophilic side chain 
intermediates 24-28, we next focused on investigating the 
simplified peptide unit in place of synthetically challenging urea-
peptide moiety of the western zone. Previously, Tanino et al. 
performed a systematic SAR study of the accessory urea-peptide 
moiety.24 In this study, diverse muraymycin analogues were 
synthesised by replacing the native L-epi-capreomycidine with 
simple amino acids such as L-arginine, L-ornithine, L-methionine 
and L-valine.24 The results from biological evaluation suggested 
that the synthetically challenging western zone could be simplified 
by using amino acids with a lipophilic side chain.24 Inspired by this 
SAR study24 which was carried out towards simplification of the 
western zone of the muraymycin structure, we planned to 
introduce a simplified amino acid spacer between the serine 
template and the lipophilic side chain. The reasoning behind the 
introduction of a spacer in between the serine template and 
lipophilic side chain was to mimic the alkyl linker which is present 
between the core 5-glycyluridine and lipophilic side chain of 
naturally occurring muraymycins.13,15 It was envisaged that 
introduction of the spacer molecule would orientate the introduced 
pharmacophores in order to best retain antibacterial activity. The 
approach employed uses different amino acids as a spacer, 
selecting them based on their varied polarity (29, Figure 7). We 
selected non-polar aromatic amino acids such as phenylalanine 
and tryptophan, a polar aromatic amino acid such as tyrosine and 
a polar aliphatic amino acid such as lysine.  
 
Figure 7. The proposed serine template (L/D-serine) linked scaffold having 
different amino acids as spacer unit 29. 
Synthesis of target molecules with the amino acid spacer 
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33 followed by linking them on to core structure of the serine 
template 21 (Scheme 5). The acid intermediates, which all contain 
different amino acids (tyrosine 30, tryptophan 31, phenylalanine 
32 and lysine 33) and a tridecanoic lipophilic side chain 
(mimicking the natural product muraymycin A1), were prepared 
by a conventional four step synthetic protocol as summarised in 
SI. With the successful synthesis of the acid intermediates 30-33, 
each was efficiently transferred to the core serine template 
structure 21 in a similar manner to the creation of compound 6. 
Following on from the successful amide coupling reaction of 21 
with the acid intermediates 30-33, the resulting amide coupled 
products were further reacted under Staudinger reaction 
conditions to produce the amino intermediates, which were all 
globally deprotected under acidic conditions to afford our final 
target molecules 34-37 (Scheme 5).  
 
Scheme 5. Reagents and conditions: a) EDC·HCl, HOBt, DMF, rt, overnight, b) PPh3, H2O, THF/toluene (1:1), 50°C, 18 h, c) aqueous TFA (80%), rt, 5-6 h, 39% 
(for compd. 34), 44% (for compd. 35), 44% (for compd. 36), 42% (for compd. 37).   
At this stage of our SAR study of simplified serine template 
analogues of muraymycins, we were interested in investigating 
stereochemical constraints related to the serine template itself 
and how this may contribute toward antibacterial activity. 
Therefore, we designed target molecules by using tyrosine and 
tryptophan as spacer molecule and tridecanoic lipophilic side 
chain, except having opposite stereochemistry of serine template 
by using D-serine as a linker. Synthesis of the target molecules 38 
and 39 was performed exactly in the same fashion except starting 
from the advanced stage precursor 22 (R, by using D-serine as 
linker) (Scheme 6).
 
Scheme 6. Reagents and conditions: a) EDC·HCl, HOBt, DMF, rt, overnight, b) PPh3, H2O, THF/toluene (1:1), 50°C, 18 h, c) aqueous TFA (80%), rt, 5-6 h, 48% 
(for compd. 38), 31% (for compd. 39).  
.
Biological Evaluation 
 All newly synthesised serine template linked muraymycins 
analogues 6,24-28,34-37,38-39 were evaluated for antibacterial 
activity against a range of clinically relevant bacterial pathogens, 
including S. aureus ATCC 43300 (methicillin-resistant), E. coli 
ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa 
ATCC 27853, A. baumannii ATCC 19606. Colistin and 
vancomycin were used as positive bacterial inhibitor standards for 
Gram-negative and Gram-positive bacteria, respectively (MIC 
values are depicted in Table 1). Interestingly, these 
microorganisms are all priority 1 (critical) or 2 (high) listed 
pathogens according to WHO classification.3 The results obtained 
from a dose response assay to determine the minimum inhibitory 
concentration (MIC) are summarised in Table 1. Each sample 
concentration was prepared in 384-well, non-binding surface 
plates (NBS; Corning 3640) for each bacterial strain. We first 
screened the core serine template analogue 6 linked with three 
pharmacophores, including uridine, aminoribose and the lipophilic 
side chain (octanoic acid). However, contrary to our expectation, 
the core serine template compound 6 did not show any 
antibacterial activity against all the screened bacterial pathogens 
(MIC > 32 g/mL). As the most active analogue of naturally 
occurring muraymycins A1 contains a lipophilic side chain of n = 
13, we were anxious to investigate the effect of increasing 
lipophilicity on antibacterial activity, comparable to that of the 
natural product. Therefore, we have synthesised and screened 
compounds 24-28 having a longer linear lipophilic side chain such 
as nonanoic 24, undecanoic 26, and tridecanoic 28 functional 
groups. We also explored molecules with higher lipophilicity, 
which contained unsaturated lipophilic side chains, such as 
undecylenic 27 and 8-nonenoic 25 functional groups. However, 
none of the lipophilic side chain analogues 24-28 showed any 
antibacterial activity against resistant bacterial pathogens (MIC > 
32 g/mL). This set of biological results suggested that increasing 
lipophilicity equivalent to that of the naturally occurring 
muraymycin A1 was also not enough to generate a significant 
antibacterial agent. Therefore, it was clear that linking only three 
key units was not sufficient to generate the bioactive scaffold. We 
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had envisaged that further optimisation of the western zone was 
therefore necessary. 
To optimise western zone of the serine template analogues, 
we planned to introduce an amino acid spacer in between the 
serine template and lipophilic side chain. As we wanted to mimic 
the lipophilicity of the natural product, we planned to retain 
linearity of n = 13 carbon chain (tridecanoic functional group) as 
present in muraymycin A1.13,15 We then selected representative 
amino acids with varying polarity such as non-polar aromatic 
(phenylalanine 36, tryptophan 35), polar aromatic (tyrosine 34), 
and polar aliphatic (lysine 37) amino acids. The antibacterial 
activity of this series of compounds was then evaluated, and the 
results are summarised in Table 1. Interestingly, compounds 
possessing tryptophan 35 and phenylalanine 36 amino acid linker 
were found to be moderately active against multiple WHO priority 
resistant strains. The phenylalanine linker containing molecule 36 
was active against S. aureus ATCC 43300 (methicillin-resistant) 
(MIC = 32 g/mL), E. coli ATCC 25922 (MIC = 32 g/mL) and          
P. aeruginosa ATCC 27853 (MIC = 32 g/mL). The tryptophan 
linker containing molecule 35 was also active against multiple 
bacterial strains, including S. aureus ATCC 43300 (methicillin-
resistant) (MIC = 32 g/mL) and A. baumannii ATCC 19606 (MIC 
= 32 g/mL). However, the tyrosine linker analogue 34, exhibited 
no antibacterial activity (MIC > 32 g/mL). Additionally, we 
investigated a polar aliphatic amino acid (lysine amino acid linker 
37) which was also found inactive. Based on the results we had 
obtained the serine template with a non-polar aromatic amino acid 
(phenylalanine and tryptophan) linker appeared to be essential for 
antibacterial activity. Conversely, the presence of a polar aromatic 
amino acid (tyrosine) or polar aliphatic amino acid (lysine) linker 
resulted in loss of antibacterial properties. Therefore, the 
antibacterial activity of our simplified serine template analogues 
was well-correlated with the presence of lipophilicity in the linker 
part of serine template scaffold. This is consistent with the 
observation by Mansour and co-workers, where lipophilicity of 
semi-synthetic muraymycin C1 analogues directly related to the 
biological activity.18d   
  After optimising the minimum structural requirement of 
serine template scaffold, we further investigated its 
stereochemical requirement towards antibacterial activity. This 
was achieved by screening two more compounds, which 
contained the D-serine template with a tryptophan 39 and tyrosine 
38 as spacers, along with the lipophilic side chain mimicking the 
natural product muraymycin A1 (n = 13 carbon length, tridecanoic 
functional group). Though having similar structural characteristics, 
these analogues 38 and 39 were designed by replacing the 
natural L-serine template with the unnatural amino acid D-serine. 
Interestingly, antimicrobial screening results for molecules 38 and 
39 were similar to that observed for the L-serine template 
analogues 34 and 35. The tryptophan linker containing molecule 
39 showed activity against multiple bacterial strains, including S. 
aureus ATCC 43300 (methicillin-resistant) (MIC = 16 g/mL) and 
A. baumannii ATCC 19606 (MIC = 32 g/mL). However, analogue 
38, the tyrosine linker, molecule had lost antibacterial activity (MIC 
> 32 g/mL). These results were in line with the previous 
observation that non-polar aromatic amino acid linkers were 
active antimicrobials, whilst polar aromatic amino acid linkers 
reduced this observed activity (MIC > 32 g/mL). These results 
also allowed us to summarise that the presence of an unnatural 
amino acid template containing D-serine, as seen for compound 
39 lead to an increase in antibacterial activity against S. aureus 
ATCC 43300 (methicillin-resistant) in comparison with the natural 
amino acid template (L-serine) 35. However, equivalent results 
were observed against A. baumannii ATCC 19606 in both cases 
(D-serine 39 and L-serine 35). These results clearly show that a 
presence of unnatural amino acid template (D-serine) replacing 
natural amino acid template (L-serine) could form either 
equipotent or more potent antibacterial scaffold. 
Next we turned to the screening of the serine template 
analogues for MraY inhibitory activity (Table 2). This 
radiochemical MraY assay was performed at 100 M final 
concentration against membranes containing overexpressed E. 
coli MraY by a previously described method.29 Interpretation of 
these results reveal that the inhibition of the MraY enzymatic 
activity does not correlate with the antibacterial activity. The most 
active hit compounds 35, 36 and 39 showed MraY inhibition of 
only 3.0%, 0.0% and 5.7%, respectively. However, in contrast the 
compounds 34 and 37 have shown significant MraY inhibition of 
25.3% and 19.7%, respectively. We believe that this contradiction 
between in vitro antibacterial activity and MraY enzyme inhibition 
could be possible due partly to uptake issues, and the possibility 
of other targets. Also, there are minor differences in the 
sequences of the MraY enzymes across different bacterial 
species,10b so it is possible that compounds 35,36 and 39 are 
more active against MraY enzymes from different bacteria.      
Table 2. The inhibitory activity of structurally simplified serine template 
analogues of muraymycins against MraY enzymea 













aAssay was performed at 100 M final concentration against membranes 
containing overexpressed E. coli MraY. This MraY enzyme inhibitory assay was 
performed with controls which included a no inhibitor negative control, and a 
positive inhibitor control tunicamycin (100 M). IC50 was measured from a plot 
of enzyme activity vs. inhibitor concentration where the negative control was 
defined as 100% activity. 
 
Selective toxicity towards bacterial strains is a key concern 
in the development of chemotherapeutics for infectious disease. 
Subsequently, determining the specificity of our synthesised 
compounds towards bacterial cells and determination of their 
toxicity towards mammalian cell is an important aspect of potential 
clinical drug development. Accordingly, the lead serine template 
analogues 35, 36 and 39 were evaluated via in-vitro cytotoxicity 
assay against human embryonic kidney cells (HEK-293, ATCC 
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CRL-1573) as well as for haemolytic assay against human red 
blood cells (RBC). The three screened serine template analogues 
35, 36 and 39 were found to be free from any significant 
cytotoxicity. However, in contrast all of them 35, 36 and 39 were 
found to be haematotoxic against human red blood cells (RBC).  
Proposed binding mode of serine template analogues 
With exact MraY inhibition data of serine template 
compounds in hand, we were interested if the relative inhibition 
potencies of our serine template analogues could be correlated to 
their structural characteristics by in silico modelling. To predict the 
putative binding mode of the most active molecules 34 and 37 
against a MraY enzyme, a combination of semi-automated 
docking and molecular dynamics (MD) simulations was employed. 
The initial structures of muraymycin D2 4 (from the crystal 
structure), molecules 34 and 37 (derived from the guided docking) 
in complex with the MraY enzyme are given in Figure S1. To 
mimic the cell membrane environment, each protein-ligand 
complex was inserted into a model lipid bilayer. The stability of 
these complexes was evaluated using the root mean square 
deviation (RMSD) of protein backbone and ligand atoms from two 
independent 50 ns MD simulations for each of the complexes. The 
RMSD plots (Figure S2) indicates that the protein is stable in all 
three complexes. The crystal structure-derived bound 
conformation of Muramycin D2 4 shows the lowest RMSD 
amongst all ligands, and validates the MD simulation protocol and 
parameters. Molecules 34 and 37 show slightly higher RMSD 
values indicating the re-arrangement of the docked conformations 
to reach a more stable state. The representative bound 
conformations of ligands obtained after 50 ns of MD simulations 
are shown in Figure 8. The key pharmacophores (GlyU and 5-
aminoribose) of 34 and 37 bind to the negatively charged cavity 
as observed for Muramycin D2 4. The rest of the pharmacophores 
(including the aliphatic chain) can hop around and bind to the 
protein surface around the cavity. The aliphatic chain inserts into 
a hydrophobic cavity at the junction of TM5 and TM9 helices. The 
aliphatic chain plays a crucial role of being an anchor and we 
believe this proposed binding of the serine template analogues 




     
Figure 8. Representative structure of muraymycin D2 4 (left) and serine template analogue 34 and 37 (middle and right, respectively) in complex with MraY from 
Aquifex aeolicus, after 50 ns of MD simulations with the position of 4 derived from the previously reported X-ray co-crystal structure21 and the position of 34 and 37 
derived from the guided docking. The electrostatic surface of the protein is shown with the colour spectrum red (negative) to white (neutral) to blue (positive) regions.
  







MIC (g/mL) Cytotoxicity 




Sa Ec Kp Pa Ab 
36 32 32 >32 32 >32 >32 11.26 
35 32 >32 >32 >32 32 >32 11.54 
39 16 >32 >32 >32 32 >32 <=0.25 
Vancomycin 1 - - - - - - 
Colistin - 0.125 0.25 0.25 0.25 - - 
a Sa (Staphylococcus aureus MRSA ATCC 43300). 
b Ec (Escherichia coli ATCC 25922); Kp (Klebsiella pneumoniae ATCC 700603); Pa (Pseudomonas aeruginosa ATCC 27853); Ab (Acinetobacter baumannii 
ATCC 19606). 
c HEK-293, Human embryonic kidney cells (ATCC CRL-1573, CC50). 
d RBC, Human red blood cells (HC50). 




In conclusion, a systematic SAR study of simplified serine 
template analogues was investigated. The simplified analogues 
of muraymycins, having their key pharmacophores linked on a 
serine template were synthesised through a multistep protocol. 
Interestingly, these compounds have shown their antibacterial 
potential against WHO priority organisms classified as priority 1 
(critical) and priority 2 (high). Initial antimicrobial screening results 
revealed that three pharmacophores, including uridine, 5-
aminoribose and the lipophilic side chain, were not enough to fulfil 
minimum structural requirements for activity. Moreover, an 
increment of linearity or unsaturation in the lipophilic side chain 
was also not efficient for generating an active scaffold. However, 
the introduction of a non-polar aromatic amino acid 
(phenylalanine and tryptophan) spacer was found to be crucial for 
affording antimicrobial activity against resistant bacterial strains. 
Furthermore, evaluation of the effect of changed stereochemistry 
within the core serine templet indicated that serine holding 
opposite stereochemistry (D-serine) either retained or increased 
antibacterial potential in the case of a non-polar aromatic amino 
acid (tryptophan) spacer. The lipophilic side chain was found to 
act as a crucial anchor for the binding and inhibition of MraY. 
Subsequently, the screening of the serine template analogues for 
enzymatic activity revealed two active hit compounds, having 
significant inhibition against overexpressed E. coli MraY enzyme. 
Moving forward, active molecules were screened for 
mammalian cell toxicity. The hit compounds were found to be non-
toxic towards human embryonic kidney cells and toxic against 
human red blood cells. Overall, the SAR study of our novel serine 
template linked molecules suggests that the complexity present 
in the naturally occurring muraymycins could be simplified to a 
large extent. On the basis of our results, the binding mode of the 
active serine template compounds with an MraY enzyme was 
proposed. The knowledge obtained from our SAR study will 
provide further direction towards the design of potent muraymycin 
analogues with simplified structural characteristics. This 
preliminary study has set the stage for a new generation of novel 
antibacterial lead compounds acting against priority 
microorganisms, specifically against the ones classified by WHO. 
Work along this line is ongoing in our laboratories, including 
determining the mode of action as well as further lead optimisation 
to achieve more potent antibacterial agents.    
Experimental Section 
Full experimental details are disclosed in the Supporting 
Information. 
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Systematic SAR study of 12 structurally simplified serine template linked muraymycin analogues were conducted. Our lead compounds 
are active against WHO priority organisms classified as priority 1 (critical) and priority 2 (high), including one Gram-positive and four 
Gram-negative bacterial strains. This preliminary investigation of serine template analogues has successfully revealed that the complex 
structure of naturally occurring muraymycins could be easily simplified to afford bioactive scaffolds active against resistant priority 
organisms and has set the stage for development of novel class of antibacterial agents. 
 
